DSIP

DSIP stands for delta sleep-inducing peptide; its official nonproprietary name is emideltide. It is a nonapeptide, a chain of nine amino acids (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu), first isolated in 1977 from the blood of rabbits after electrical stimulation of the thalamus, and early experiments showed it had sleep-inducing properties. In the US it is offered as injections and nasal products through wellness and concierge clinics and online retailers, none of them FDA-approved.

Probably not in any meaningful way, going by the small trials that exist. In a 1992 double-blind trial, 16 people with chronic insomnia received IV DSIP or placebo over three nights; the authors concluded that “short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit.” A 1987 study of 14 people with severe chronic insomnia reported improved sleep, but it was small. Researchers have never found a DSIP gene or receptor, so how it would act on sleep is unknown. If you have trouble sleeping, talk with your doctor.

On July 24, 2026 the FDA’s Pharmacy Compounding Advisory Committee reviewed emideltide for opioid withdrawal, chronic insomnia and narcolepsy. FDA staff found “insufficient evidence” for all three by IV infusion and “did not identify any data” for injection under the skin, the route proposed. The committee recommended six other peptides but “rejected adding a seventh peptide, emideltide, to the list, citing especially weak evidence.”

Not according to the FDA. Its 2026 review states that “emideltide (free base) and emideltide acetate are not registered drugs in any country searched,” and that no form of emideltide is recognized in the European, Japanese or International Pharmacopoeia. It is not FDA-approved for any use.

Very short. The FDA’s review states that “emideltide has a short plasma half-life of 8 minutes,” and a 1987 lab study found half-lives of 5 to 10 minutes in human serum.

Solubility matters more than usual with DSIP. The FDA’s 2026 review cites reports that emideltide free base dissolves in water at only 0.5 mg/mL. At that figure, 5 mg of the free base would need about 10 mL of water to dissolve fully (an example, not a dose), more than many small vials can hold; see how much water a vial can hold. The same review cites reports that the dry powder is stable at room temperature for 3 weeks. The reconstitution calculator shows the concentration any volume makes. Because this product is not FDA-approved, no official label sets a water volume, and the contents of unapproved vials are not verified. Talk to a licensed prescriber or pharmacist before using any unapproved product.